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ABSTRACT (word count 248, maximum 260 words) 
Background & Aims Gastroesophageal reflux disease (GERD) affects up to 30% of adults in Western 
populations and is increasing in prevalence. GERD is associated with lifestyle factors, particularly 
obesity and tobacco smoking, and carries a risk of several adverse outcomes, including esophageal 
adenocarcinoma. The aim of this systematic review was to assess the role of lifestyle intervention in 
the treatment of GERD. 
Methods Literature searches were performed in PubMed (from 1946), EMBASE (from 1980), and the 
Cochrane Library (no start date) to October 1, 2014. Meta-analyses, systematic reviews, randomized 
clinical trials (RCTs) and prospective observational studies were included. 
Results Weight loss was followed by decreased time with esophageal acid exposure in two RCTs 
(from 5.6% to 3.7% and from 8.0% to 5.5%, respectively), and reduced reflux symptoms in 
prospective observational studies. Tobacco smoking cessation reduced reflux symptoms in normal 
weight individuals in a large prospective cohort study (odds ratio 5.67). In RCTs, late evening meals 
increased time with supine acid exposure compared to early meals (5.2% points change), and head of 
the bed elevation decreased time with supine acid exposure compared to a flat position (from 21% to 
15%). In a placebo-controlled RCT, high dietary fiber intake decreased heartburn. 
Conclusions Weight loss and tobacco smoking cessation should be recommended to GERD patients 
who are obese and smoke, respectively. Avoiding late evening meals and head of the bed elevation is 
effective in nocturnal GERD and high dietary fiber intake might reduce heartburn. 
Keywords: GERD; heartburn; acid regurgitation; therapy; treatment 
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MAIN TEXT (word count 3,398, maximum 6,000 words, including figure and table legends, and 
references)  
Gastroesophageal reflux disease (GERD), defined by at least weekly symptoms of heartburn or acid 
regurgitation, is increasingly common.1 The prevalence in adults ranges from 30% in some Western 
populations to below 10% in East Asian populations, and the incidence is about 5/1000 person-years 
in Western populations.1 GERD is associated with reduced health-related quality of life,2 decreased 
work productivity3 and increased risk of esophageal adenocarcinoma.4 The annual incidence of 
esophageal adenocarcinoma is increasing worldwide, from 3.5% in Scotland to 8.1% in Hawaii, which 
parallels the increasing prevalence of GERD.5 In addition, GERD diagnostic tests and treatments carry 
high societal costs.6 
The pathophysiology of GERD is dominated by functional and anatomic defects at the 
gastroesophageal junction, including reduced pressure and increased reflux episodes associated with 
transient relaxations of the lower esophageal sphincter and formation of hiatal hernia which 
promotes and facilitates reflux.7-9 Esophageal motility and salivary bicarbonate contribute to 
esophageal acid clearance and buffering, respectively, and reduce acid contact time in the 
esophagus.10,11 Visceral obesity increases the pressure over the gastroesophageal junction, thus 
facilitating reflux,12 while tobacco smoking reduces the lower esophageal sphincter pressure and 
salivary bicarbonate secretion, which facilitates reflux and decreases acid buffering, respectively.13,14 
The main established risk factors of GERD are heredity, obesity and tobacco smoking.15-18 High 
dietary fiber intake and moderate physical exercise seem to reduce this risk,18 while sex and age do 
not strongly influence the risk of GERD.19,20 Obesity is of particular interest since it is increasing in 
prevalence in parallel with GERD, and several studies have shown an increased risk of GERD and 
esophagitis with obesity, especially abdominal obesity.21,22  
GERD is typically diagnosed by the cardinal symptoms heartburn or acid regurgitation23 and symptom 
resolution following acid-inhibition with a proton pump inhibitor (PPI).24,25 If symptoms do not 
5 
 
resolve, endoscopy is usually performed and mucosal erosions (esophagitis) or peptic strictures are 
diagnostic of GERD.26 Endoscopy can also reveal Barrett’s esophagus, a premalignant columnar 
metaplasia, and esophageal adenocarcinoma. If endoscopy is normal, esophageal pH-measurement 
can still reveal pathologic acid reflux (pH <4).27 The pH-measurement can be combined with 
impedance-measurement to detect reflux of weakly acidic or non-acidic liquid and gas, which can 
cause reflux symptoms refractory to acid inhibition.28 
The treatment of GERD is primarily by medication with antacids, H2-receptor antagonists and PPIs, 
while surgery with fundoplication is used in selected patients. Surgery carries a risk of adverse 
events, including postoperative complaints of dysphagia, flatulence and inability to belch or vomit.29 
Recent evidence also shows that long-term PPI medication is hampered by adverse effects. This 
includes secondary hypergastrinemia and rebound acid hypersecretion, inducing reflux symptoms at 
withdrawal of PPI medication;30 increased risk of enteric infections and community acquired 
pneumonia, probably due to increased gastric pH causing reduced host defence;31,32 and increased 
risk of hip and vertebral fractures, probably due to malabsorption of calcium.33 
This review addresses lifestyle intervention in the treatment of GERD and compares existing evidence 
with current guidelines. 
  
METHODS 
Systematic literature searches on lifestyle intervention in GERD were performed in MEDLINE using 
PubMed from 1946 and EMBASE using OvidSP from 1980 to October 1, 2014. In addition, the 
Cochrane Library was searched, last time October 1, 2014. The searches included thesaurus terms 
(MeSH in MEDLINE and EMTREE in EMBASE): “gastroesophageal reflux”, “heartburn”, “peptic 
esophagitis” (EMBASE)/”esophagitis, peptic” (MEDLINE) and “non-erosive reflux disease” (EMBASE). 
Randomized clinical trials (RCTs), prospective observational studies, and meta-analyses and 
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systematic reviews of RCTs or observational studies of GERD patients were included. The searches 
were limited to the English language and research on adult humans. The evidence of interventions 
was graded using the American Heart Association’s guidelines: Multiple populations evaluated, data 
derived from multiple RCTs or meta-analyses (Level A); limited populations evaluated, data derived 
from a single RCT or non-randomized studies (Level B); and very limited populations evaluated, only 
consensus opinion of experts, case studies or standard of care (Level C).  
 
RESULTS 
Literature searches 
Literature searches on lifestyle intervention identified 579 and 453 studies in MEDLINE and EMBASE, 
respectively, of which 15 met the inclusion criteria (Figure, Table and eTable). No Cochrane reviews 
on lifestyle intervention in GERD were identified. Four management guidelines were assessed: the 
Canadian Association of Gastroenterology (CAG) consensus (2005);24 the American College of 
Gastroenterology (ACG) practice guidelines (2005);25 the American Gastroenterological Association 
(AGA) medical position statement and technical review (2008);34,35 and a more recent guideline by 
Katz et al. (2013).36  
 
Lifestyle interventions 
Lifestyle interventions in GERD have traditionally included avoidance of foods that may precipitate 
reflux episodes and heartburn (e.g., coffee, alcohol, chocolate, peppermint, citrus, carbonated drinks 
and spicy foods) and behavioral changes with weight loss, smoking cessation, head of bed elevation, 
avoiding large meals and avoiding recumbence after meals or meals before bedtime.34,35 Until 
recently, these interventions were mainly based on case series.37 However, new supportive evidence 
has emerged. 
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Weight loss 
Three RCTs in severely obese individuals compared weight loss by gastric balloon distension with 
sham treatment combined with dietary guidance, physical exercise and behavioral therapy, and 
showed reduced esophageal acid exposure with weight loss.38-40 In the first RCT, including 17 
patients, 3 of 5 patients with pathological pH-measurements got normalized pH-measurements with 
weight loss of 31.3-44.0 kg after 4 months.38 In the second RCT, 23 patients with a mean weight loss 
of 11.2 kg within 13 weeks had decreased time with esophageal pH <4 (from 5.60% to 3.72%, P 
<0.05).39 Moreover, there was a strong correlation between decreased waist circumference and 
acidic reflux time (r=0.78, P=0.000).39 These results were supported by the third RCT of 17 sham 
treated patients, where mean weight loss of 12.5 kg within 13 weeks improved time with upright pH 
<4 (from 8.0% to 5.5%, P <0.05).40 
A larger RCT compared obese participants randomized to a structured weight loss program (n=167) 
or a telephone-based group conference on weight management (n=165). The prevalence of reflux 
symptoms decreased (from 37% to 15%, P <0.01) and the symptom score improved (Reflux Disease 
Questionnaire, P <0.01) after 6 months of weight loss (mean body mass index (BMI) decreased from 
34.7 to 30.2), irrespective of treatment group.41 
These results were confirmed in 2 uncontrolled prospective cohort studies of GERD patients.42,43 A 
study of 8 extremely obese patients (mean BMI 43.5) showed significant improved total time with pH 
<4 (from 5.1% to 2.5%, P=0.022) and reflux symptoms score (Distress Subscale of Gastroesophageal 
Reflux Disease Symptom Assessment Scale from 1.28 to 0.72, P=0.0004) after 4 days on a very low-
carbohydrate diet and a mean weight loss of 1.7 kg.42 Moreover, a study of 34 patients with mean 
BMI of only 23.5, reflux symptoms and either normal endoscopy or low grade esophagitis also 
showed significant correlation between weight loss after dietary advice (mean BMI decrease 1.7) and 
reflux symptom score (modified DeMeester questionnaire, r=0.548, P <0.001).43 
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Two large prospective population-based cohort studies showed that weight reduction dose-
dependently decreased reflux symptoms.44,45  The Nurses’ Health Study, an observational cohort 
study of 10,545 women, showed a dose-dependently reduced risk of reflux symptoms among women 
who had decrease in BMI compared to women with no BMI change (odds ratio (OR) 0.64, 95% 
confidence interval (CI) 0.42-0.97 with >3.5 units decrease in BMI, P for trend <0.001).44 The HUNT 
study, a prospective population-based cohort study of 29,610 participants also showed a dose-
dependent association between weight loss and the chance of losing reflux symptoms (OR 2.42, 95% 
CI 1.88-3.11 with >3.5 units decrease in BMI, P for trend <0.001). In this study, decrease in BMI was 
also associated with an increased chance of losing reflux symptoms with medical treatment (OR 1.98, 
95% CI 1.45-2.72 with >3.5 units decrease in BMI and no or less than weekly medication compared to 
OR 3.96, 95% CI 2.03-7.65 with >3.5 units decrease in BMI and at least weekly medication).45 
Challenging these results, a small RCT showed that weight loss (mean 10.8 kg) did not have 
significant effects on symptoms, esophagitis or pH-measurements in obese patients (mean 
BMI=31.4) with GERD who were randomized to a low-caloric diet (430 kcal/day) for 6 months (n=10) 
or not (n=9).46 This might be explained by the inclusion of patients with hiatal hernia, which is not 
reversible with weight loss. In addition, a prospective population-based cohort study of 637 
individuals showed no association between weight loss and reflux symptoms, but since weight loss 
was self-reported it might be overestimated.47 
 
Tobacco smoking cessation 
A prospective population-based cohort study (the HUNT study) of 29,610 participants showed that 
smoking cessation was associated with decreased severe reflux symptoms in normal weight 
individuals on medical treatment, compared to participants who continued smoking daily (OR 5.67, 
95% CI 1.36-23.64).48 However, there was no similar association in overweight (BMI 25.0-29.9) or 
obese (BMI ≥30.0) individuals (OR 1.24, 95% CI 0.57-2.71 and OR 1.29, 95% CI 0.53-3.17, 
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respectively). A possible explanation for these findings is that GERD pathophysiology in obese 
individuals is strongly dictated by weight, while smoking plays a minor role, but smoking is a more 
important factor in non-obese individuals.  
 
Dietary interventions 
A RCT showed no influence of weight loss following a 6 month period of low-caloric diet (430 
kcal/day) on GERD.46 However, a small non-randomized study of 8 severely obese patients (mean 
BMI=43.5) who lost weight (1.7 kg) on a 4-day very low-carbohydrate diet (<20g/day) showed a 
decreased total time with pH <4 (from 5.1% to 2.5%, P=0.022) and reflux symptoms score (from 1.28 
to 0.72, P=0.0004).42 
A crossover RCT of 30 patients randomized to a late meal (2 hours before bedtime) or an early meal 
(6 hours before bedtime) showed more pH-verified supine reflux after the late evening meal (mean 
change 5.2%, P=0.002).49 
A RCT that compared patients using a dietary fiber product (n=15) with placebo (n=15) for 2 weeks, 
showed an increased number of days without heartburn (mean 1.87 and 0.73, respectively, P <0.05) 
and reduced severity score (mean 7.7 and 13.3, respectively, P <0.05) in the fiber group.50 
A systematic review based on observational studies showed no evidence of carbonated beverages 
promoting GERD.51 
Regarding other potential dietary interventions there were no studies meeting the search criteria. 
 
Head of bed elevation 
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A systematic review concluded that head of the bed elevation could reduce GERD,37 based on one 
crossover RCT of 15 GERD participants, where elevation of the head of the bed by a 10 inch wedge 
decreased esophageal pH <4 time compared to a flat position (15% and 21%, respectively, P <0.05).52 
 
DISCUSSION 
RCTs have shown reduced reflux symptoms and esophageal acid exposure with weight loss,38-41 
findings supported by well-designed observational studies showing a dose-dependent decreased 
presence of reflux symptoms following weight reduction. A large prospective observational study 
showed reduced reflux symptoms with tobacco smoking cessation in normal weight individuals.48 
RCTs also showed that early evening meals49 and head of the bed elevation52 decreased the 
esophageal acid exposure time, and dietary fiber decreased reflux symptoms.50 
Based on the present review, we believe that the evidence of lifestyle modifications in GERD has 
been strengthened compared to the statements in the four current treatment guidelines.24,25,34-36 The 
CAG guideline concludes that lifestyle modifications are ineffective for frequent or severe reflux 
symptoms and that data are insufficient to support lifestyle modifications in mild reflux.24 The ACG 
guideline states that lifestyle modification may benefit some GERD patients, but that such 
modifications alone are unlikely to control symptoms in the majority of GERD patients.25 The AGA 
guideline recommends weight loss in obese GERD patients and elevation of the head of the bed in 
patients experiencing reflux symptoms when recumbent, while other lifestyle modifications should 
be individually tailored.34,35 The guideline by Katz et al. supports avoidance of meals two to three 
hours before bedtime, in addition to weight loss and head of bed elevation. However, it does not 
recommend elimination of food that can trigger reflux.36 
We believe that patients suffering from GERD should be recommended to lose weight if they are 
obese, that tobacco smoking cessation and increased dietary fiber should be encouraged and that 
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late evening meals should be avoided and head of the bed elevation recommended for patients with 
supine reflux. Lifestyle interventions, especially weight loss and tobacco smoking cessation, are also 
beneficial from other perspectives, including low economic costs, no harmful side-effects and overall 
health benefits.  
As only small RCTs or observational studies of lifestyle intervention have been performed, larger 
RCTs should be conducted to verify these results. Nevertheless, the available evidence is reasonably 
consistent and supported by the pathophysiology and epidemiology. The effects of these 
interventions on reflux symptoms, acid exposure and endoscopic findings should be assessed in 
future studies. As obesity and smoking are risk factors of GERD, reduced prevalence of these 
exposures in the populations could also reduce the incidence of GERD.  
 
CONCLUSIONS 
Recent evidence supports lifestyle intervention in the treatment of GERD. These include weight loss, 
tobacco smoking cessation, dietary interventions and head of the bed elevation. Meanwhile, the 
awareness of adverse effects of medical treatment has increased, questioning long-term and 
continuous PPI therapy, at least in mild GERD. 
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TABLE 
Table. Lifestyle intervention in gastroesophageal reflux disease (GERD) 
                   
            
Comparison with current guidelines 
Category   Study   Design   Intervention   Findings   
Level of 
evidence
a
   CAG
b
   ACG
c
   AGA
d
   Katz et al. 
                   Weight loss  Mathus-Vliegen 
et al. 1996 
 RCT
e
  Gastric balloon vs. 
sham treatment 
 Normalization of pH-
measurements in 3 of 
5 with weight loss   
A 
  
Lifestyle 
modifications 
are ineffective 
for frequent or 
severe 
symptoms, but 
may be 
beneficial if 
obvious 
dietary 
precipitants, 
obesity or 
tobacco 
smoking 
  
Lifestyle 
modifications 
may benefit 
many GERD 
patients, but 
are unlikely to 
control 
symptoms in 
the majority 
  
Weight loss in 
obese 
patients, head 
of the bed 
elevation if 
symptoms 
when 
recumbent 
and other 
lifestyle 
modifications 
tailored to the 
individual 
patient 
  
Weight loss 
recommended 
for GERD 
patients with 
overweight or 
recent weight 
gain; Head of 
bed elevation 
and avoidance 
of meals 2 – 3  
hour before 
bedtime 
recommended 
if nocturnal 
GERD; Routine 
global 
elimination of 
food that can 
trigger reflux 
not 
recommended 
         
       Mathus-Vliegen 
et al. 2002 
 RCT
e
  Gastric balloon vs. 
sham treatment 
 Reduced acid 
exposure in sham 
group (the effect of 
mere weight loss) 
              
         Mathus-Vliegen 
et al. 2003 
  RCT
e
   Gastric balloon vs. 
sham treatment 
  Reduced acid 
exposure in sham 
group (the effect of 
mere weight loss)           
         
       Singh et al. 2013  RCT
e
  Structured weight 
loss program vs. 
telephone-based 
group conference 
 Decreased symptom 
prevalence and score 
in both groups 
              
         Austin et al. 
2006 
  Non-randomized 
prospective study 
  Very low-
carbohydrate diet  
  Decreased acid 
exposure and 
symptom score           
         
       Fraser-Moodie 
et al. 1999 
 Non-randomized 
prospective study 
 Dietary advice  Decreased symptom 
score 
              
         Jacobson et al. 
2006 
  Prospective 
population-based 
cohort study 
  No intervention   Dose-dependent 
decrease in symptom 
prevalence           
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       Ness-Jensen et 
al. 2013 
 Prospective 
population-based 
cohort study 
 No intervention  Dose-dependent 
decrease in 
symptoms, improved 
medical treatment 
success 
              
         Cremonini et al. 
2006 
  Prospective 
population-based 
cohort study 
  No intervention   No association with 
symptoms 
          
         
       Kjellin et al. 
1996 
 RCT
e
  Low-caloric diet 
vs. control 
 No effect on 
symptoms, 
endoscopic findings or 
acid exposure 
              
      Tobacco 
smoking 
cessation 
  Ness-Jensen et 
al. 2013 
  Prospective 
population-based 
cohort study 
  No intervention   Decreased symptoms 
in normal weight 
individuals   
B 
        
         
 
 
    Dietary 
interventions 
 Kjellin et al. 
1996 
 RCT
e
  Low-caloric diet 
vs. control 
 No effect on 
symptoms, 
endoscopic findings or 
acid exposure 
 
B (no effect) 
             
 
 
        Austin et al. 
2006 
  Non-randomized 
prospective study 
  Very low-
carbohydrate diet  
  Decreased acid 
exposure and 
symptom score   
B 
        
         
 
 
      Piesman et al. 
2007 
 RCT
e
  Late vs. early 
evening meal 
 Decreased acid 
exposure with early 
evening meal 
 
B 
             
 
 
        DiSilvestro et al. 
2011 
  RCT
e
   Dietary fiber vs. 
placebo 
  Decreased symptom 
prevalence and score 
with dietary fiber   
B 
        
         
 
 
      Johnson et al. 
2010 
 Systematic review 
of observational 
 Carbonated 
beverages 
 No effect on GERD 
 
B (no effect) 
    
19 
 
studies 
         
 
 
    Head of the 
bed 
elevation 
  Hamilton et al. 
1988 
  RCT
e
   Head of bed 
elevation vs. flat 
position 
  Decreased acid 
exposure with head of 
bed elevation   
B 
        
  
  
a
A - Multiple populations evaluated, data derived from multiple randomized clinical trials or meta-analyses; B - Limited populations evaluated, data derived from a single randomized clinical trial or non-
randomized studies; C - Very limited populations evaluated, only consensus opinion of experts, case studies or standard of care. 
b
Canadian Association of Gastroenterology. 
c
American College of 
Gastroenterology. 
d
American Gastroenterological Association. 
e
Randomized clinical trial. 
 
 579 articles identified in MEDLINE 
from 1946 to October 1, 2014 
453 articles identified in EMBASE 
from 1980 to October 1, 2014 
565 articles excluded: 
 
87 not English 
14 not human 
230 not adult 
25 retrospective/cross-
sectional studies 
72 case/experimental 
studies 
109 not relevant 
patients/outcome 
6 non-systematic 
reviews 
12 no abstract available 
2 duplicates 
8 others 
445 articles excluded: 
 
42 not English 
32 not human 
213 not adult 
12 retrospective/cross-
sectional studies 
38 case/experimental 
studies 
95 not relevant 
patients/outcome 
3 non-systematic 
reviews 
2 no abstract available 
4 conference abstracts 
2 duplicates 
2 others 
15 articles included: 
 
1 systematic review 
 
8 randomized 
controlled trials 
 
6 prospective 
observational 
studies 
eTable. Summary of literature search 
                          
Source   Search terms   
Id. 
articles   Incl   
Meta-
analysis 
Systematic 
review 
Randomized 
clinical trial 
Prospective 
observational 
study   Excl   
Not 
English 
Not 
human 
Not 
adult 
Retrospect
/cross-sect 
study 
Case/ 
experim 
study 
Not relevant 
patients/ 
outcome 
Non-
systematic 
review 
No abst 
available 
Conf 
abstract Dupl Other 
                          
MEDLINE/
PubMeda 
1946 -    
Oct 1, 
2014 
  "Body Weight 
Changes"[Mesh] 
  201   8       4 4   141   21 3 88 1 4 23   1       
                    Singh et al. 
2013 
Ness-Jensen et 
al. 2013 
                            
                    Kjellin et al. 
1996 
Cremonini et 
al. 2006 
                            
                    Mathus-
Vliegen et al. 
2002 
Jacobson et al. 
2006 
                            
                    Mathus-
Vliegen et al. 
2003 
Fraser-Moodie 
et al. 1999 
                            
                                                    
    Excluding 
obesity surgery 
  -52   0             0                         
                          
  "Smoking 
Cessation" 
[Mesh] 
 12  1     1  11  3  4 1 1 2      
           Ness-Jensen et 
al. 2013 
              
                          
     "Diet 
Therapy"[Mesh] 
  72   1         1   71   22 4 27 1 1 9 2 3   2   
                    (Kjellin et al. 
1996) 
Austin et al. 
2006 
                            
                      (Fraser-
Moodie et al. 
1999) 
                            
                          
  "Meals"[Mesh]  6  0       6  1  2        3 
                          
                          
eTable. Continued 
                          
Source   Search terms   
Id. 
articles   Incl   
Meta-
analysis 
Systematic 
review 
Randomized 
clinical trial 
Prospective 
observational 
study   Excl   
Not 
English 
Not 
human 
Not 
adult 
Retrospect
/cross-sect 
study 
Case/ 
experim 
study 
Not relevant 
patients/ 
outcome 
Non-
systematic 
review 
No abst 
available 
Conf 
abstract Dupl Other 
                          
    "Dietary 
Fats"[Mesh] 
  54   0             54   8   21 4 12 6   3       
                          
  "Dietary 
Carbohydrates" 
[Mesh] 
 17  0       17  1  10 1 3 2      
                          
    "Cacao"[Mesh]   5   0             5       2   2     1       
                          
  "Mentha 
piperita"[Mesh] 
 1  0       1        1     
                          
    "Coffee"[Mesh]   20   0             20   4   1 3 5 5 2         
                          
  "Ethanol"[Mesh]  32  0       32  12 4 8  4 3     1 
                          
    "Citrus"[Mesh]   18   0             18     1 4   3 7   2     1 
                          
  "Carbonated 
Beverages" 
[Mesh] 
 37  1   1    36  1  13 1 5 12  1   3 
         Johnson et 
al. 2010 
                
                          
    "Spices"[Mesh]   6   0             6   1   3   1 1           
                          
  "Dietary 
Fiber"[Mesh] 
 23  1    1   22  3 2 7 2 2 5  1    
          DiSilvestro et 
al. 2011 
               
                          
                          
                          
eTable. Continued 
                          
Source   Search terms   
Id. 
articles   Incl   
Meta-
analysis 
Systematic 
review 
Randomized 
clinical trial 
Prospective 
observational 
study   Excl   
Not 
English 
Not 
human 
Not 
adult 
Retrospect
/cross-sect 
study 
Case/ 
experim 
study 
Not relevant 
patients/ 
outcome 
Non-
systematic 
review 
No abst 
available 
Conf 
abstract Dupl Other 
                          
    "Posture"[Mesh]
c 
  73   2       2     71   6   28 1 8 28           
                    Piesman et 
al. 2007 
                              
                    Hamilton et 
al. 1988 
                              
                          
  "Exercise" 
[Mesh] 
 54  0       54  4  12 10 21 6 1     
                          
    Sum   579   14   0 1 7 6   565   87 14 230 25 72 109 6 12 0 2 8 
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
                          
eTable. Continued 
                          
Source   Search terms   
Id. 
articles   Incl   
Meta-
analysis 
Systematic 
review 
Randomized 
clinical trial 
Prospective 
observational 
study   Excl   
Not 
English 
Not 
human 
Not 
adult 
Retrospect
/cross-sect 
study 
Case/ 
experim 
study 
Not relevant 
patients/ 
outcome 
Non-
systematic 
review 
No abst 
available 
Conf 
abstract Dupl Other 
                          
EMBASE/ 
OvidSPb 
1980 -    
Oct 1, 
2014 
  weight 
reduction 
  104   6       4 2   73   3 6 35   1 27     1     
                    Singh et al. 
2013 
Ness-Jensen et 
al. 2013 
                            
                    Mathus-
Vliegen et al. 
1996 
Fraser-Moodie 
et al. 1999 
                            
                    Mathus-
Vliegen et al. 
2002 
                              
                    Mathus-
Vliegen et al. 
2003 
                              
                                                    
    excluding 
obesity surgery 
  -25   0             0                         
                          
  smoking 
cessation 
 65  1     1  64  2 0 42  1 17   2   
           Ness-Jensen et 
al. 2013 
              
                          
    diet therapy   38   1         1   37   5 5 22     5           
                      Austin et al. 
2006 
                            
                          
  diet  51  0       51  10 6 21 3 1 10      
                          
    meals   11   0             11   2   4   2 3           
 
 
 
eTable. Continued 
                          
Source   Search terms   
Id. 
articles   Incl   
Meta-
analysis 
Systematic 
review 
Randomized 
clinical trial 
Prospective 
observational 
study   Excl   
Not 
English 
Not 
human 
Not 
adult 
Retrospect
/cross-sect 
study 
Case/ 
experim 
study 
Not relevant 
patients/ 
outcome 
Non-
systematic 
review 
No abst 
available 
Conf 
abstract Dupl Other 
                          
  fat  6  0       6    2  3 1      
                          
    carbohydrate   6   0             6       3   2       1     
                          
  cacao  2  0       2      1 1      
                          
    mentha piperita   1   0             1               1         
                          
  coffee  14  0       14  1  7 1 1 4      
                          
    alcohol   44   0             44   11 4 16 1 2 7 1       2 
                          
  citrus  0  0       0             
                          
    carbonated 
beverages 
  10   0             10     1 5   3 1           
                          
  spices  1  0       1       1      
                          
    dietary fiber   21   0             21       9 1 2 7   1   1   
                          
  posture  47  0       47  5 8 23 1 6 3  1    
                          
    exercise OR 
physical activity 
  57   0             57   3 2 24 5 13 8 1     1   
                          
    Sum   453   8   0 0 4 4   445   42 32 213 12 38 95 3 2 4 2 2 
                          aMeSH terms (exploded, including all subheadings): ("Gastroesophageal Reflux"[Mesh] OR "Heartburn"[Mesh] OR "Esophagitis, Peptic"[Mesh]) AND (…) 
bEMTREEE terms (exploded outcome, focused intervention, including all subheadings): (gastroesophageal reflux OR heartburn OR non erosive reflux disease OR reflux esophagitis) AND (…) 
cSearch limited to meta-analysis, systematic review, clinical trial and observational study 
 
